Cormorant Asset Management as of March 31, 2020
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 69 positions in its portfolio as reported in the March 2020 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Spdr S&p 500 Etf (SPY) | 12.0 | $258M | 1.0M | 257.75 | |
Turning Point Therapeutics I | 6.3 | $137M | 3.1M | 44.66 | |
Principia Biopharma | 5.8 | $125M | 2.1M | 59.38 | |
Chemocentryx | 4.9 | $107M | 2.7M | 40.18 | |
Reata Pharmaceuticals Inc Cl A | 4.9 | $106M | 737k | 144.34 | |
Mirati Therapeutics | 4.8 | $104M | 1.4M | 76.87 | |
Bridgebio Pharma (BBIO) | 4.0 | $86M | 3.0M | 29.00 | |
Acceleron Pharma | 3.4 | $74M | 825k | 89.87 | |
Ascendis Pharma A S (ASND) | 3.1 | $68M | 600k | 112.61 | |
Viela Bio | 3.1 | $67M | 1.8M | 38.00 | |
Constellation Pharmceticls I | 3.0 | $64M | 2.0M | 31.43 | |
Apellis Pharmaceuticals (APLS) | 2.8 | $61M | 2.3M | 26.79 | |
Revolution Medicines (RVMD) | 2.8 | $61M | 2.8M | 21.91 | |
Eidos Therapeutics | 2.5 | $54M | 1.1M | 48.99 | |
Y Mabs Therapeutics (YMAB) | 2.1 | $45M | 1.7M | 26.10 | |
Stoke Therapeutics (STOK) | 1.8 | $39M | 1.7M | 22.90 | |
Omeros Corporation (OMER) | 1.6 | $34M | 2.5M | 13.37 | |
Myokardia | 1.5 | $33M | 700k | 46.88 | |
Agenus | 1.4 | $30M | 12M | 2.45 | |
Biohaven Pharmaceutical Holding | 1.4 | $30M | 876k | 34.03 | |
Axsome Therapeutics (AXSM) | 1.4 | $29M | 500k | 58.83 | |
Nextcure (NXTC) | 1.3 | $28M | 743k | 37.07 | |
Crispr Therapeutics (CRSP) | 1.2 | $27M | 630k | 42.41 | |
Blueprint Medicines (BPMC) | 1.2 | $26M | 450k | 58.48 | |
Zymeworks | 1.2 | $25M | 700k | 35.47 | |
Igm Biosciences (IGMS) | 1.1 | $24M | 426k | 56.15 | |
Rocket Pharmaceuticals (RCKT) | 1.0 | $22M | 1.6M | 13.95 | |
Twist Bioscience Corp (TWST) | 1.0 | $21M | 687k | 30.58 | |
Axonics Modulation Technolog (AXNX) | 0.9 | $20M | 800k | 25.41 | |
Galapagos Nv- (GLPG) | 0.9 | $20M | 99k | 199.60 | |
Myovant Sciences | 0.9 | $20M | 2.6M | 7.55 | |
Immunovant Inc unit 12/18/2024 (IMVTU) | 0.9 | $19M | 1.1M | 17.99 | |
Tricida | 0.9 | $19M | 878k | 22.00 | |
Satsuma Pharmaceuticals Ord | 0.8 | $17M | 808k | 21.52 | |
Anaptysbio Inc Common (ANAB) | 0.7 | $16M | 1.1M | 14.13 | |
Cabaletta Bio (CABA) | 0.7 | $15M | 2.1M | 7.30 | |
Zai Lab (ZLAB) | 0.7 | $15M | 289k | 51.48 | |
Sarepta Therapeutics (SRPT) | 0.7 | $15M | 150k | 97.82 | |
Deciphera Pharmaceuticals | 0.7 | $14M | 350k | 41.17 | |
Beam Therapeutics (BEAM) | 0.7 | $14M | 796k | 18.00 | |
Akero Therapeutics (AKRO) | 0.6 | $14M | 643k | 21.20 | |
Quotient | 0.6 | $13M | 3.2M | 3.95 | |
Uniqure Nv (QURE) | 0.6 | $12M | 250k | 47.45 | |
Argenx Se (ARGX) | 0.5 | $11M | 80k | 131.72 | |
Homology Medicines | 0.4 | $9.3M | 600k | 15.54 | |
Sorrento Therapeutics (SRNE) | 0.4 | $9.2M | 5.0M | 1.84 | |
Inspire Med Sys (INSP) | 0.4 | $9.0M | 150k | 60.28 | |
Allakos (ALLK) | 0.4 | $8.9M | 200k | 44.49 | |
Kura Oncology (KURA) | 0.4 | $8.0M | 800k | 9.95 | |
Harpoon Therapeutics | 0.3 | $7.5M | 650k | 11.58 | |
Merus N V (MRUS) | 0.3 | $7.3M | 600k | 12.10 | |
Insmed (INSM) | 0.3 | $5.8M | 362k | 16.03 | |
Eiger Biopharmaceuticals | 0.3 | $5.5M | 815k | 6.80 | |
Atreca Inc Cl A (BCEL) | 0.3 | $5.4M | 326k | 16.55 | |
Avrobio Ord (AVRO) | 0.2 | $4.9M | 318k | 15.56 | |
Arena Pharmaceuticals | 0.2 | $4.2M | 100k | 42.00 | |
Minerva Neurosciences | 0.2 | $3.7M | 608k | 6.02 | |
Amarin Corporation (AMRN) | 0.2 | $3.6M | 900k | 4.00 | |
Arcturus Therapeutics Hldg I (ARCT) | 0.2 | $3.6M | 262k | 13.59 | |
X4 Pharmaceuticals (XFOR) | 0.2 | $3.4M | 342k | 10.00 | |
Autolus Therapeutics Plc spon ads (AUTL) | 0.1 | $2.9M | 480k | 5.99 | |
Nektar Therapeutics (NKTR) | 0.1 | $2.7M | 150k | 17.85 | |
Theravance Biopharma (TBPH) | 0.1 | $2.3M | 100k | 23.11 | |
Neurocrine Biosciences (NBIX) | 0.1 | $2.2M | 25k | 86.56 | |
Precision Biosciences Ord | 0.1 | $2.1M | 347k | 6.03 | |
Gossamer Bio (GOSS) | 0.1 | $2.0M | 198k | 10.15 | |
Orchard Therapeutics Plc ads | 0.1 | $1.9M | 257k | 7.53 | |
Fate Therapeutics (FATE) | 0.1 | $1.7M | 75k | 22.21 | |
Outlook Therapeutics Inc *w exp 02/18/201 | 0.0 | $65k | 417k | 0.16 |